ADPT

SEC source: 0001062993-25-009837 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,325

SEC source: 0001062993-25-008509 · form4.xml · derivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 68,412 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

F3 · derivative.exercise_date: The option was fully vested and exercisable.

SEC source: 0001062993-25-008509 · form4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,279,524

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.18 to 7.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-008509 · form4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,347,936

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

SEC source: 0001062993-25-006335 · form4.xml · derivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,412

Underlying: Common Stock · 1,698 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-25-006335 · form4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,279,524

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $9.00 to 9.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-006335 · form4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,281,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024.

SEC source: 0001062993-25-005645 · form4.xml · derivative · entry 2

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires 2026-11-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was fully vested and exercisable.

SEC source: 0001062993-25-005645 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-25-005644 · form4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,394

F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.15 to $7.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-005300 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,690

SEC source: 0001062993-25-005299 · form4.xml · derivative · entry 3

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was fully vested and exercisable.

SEC source: 0001062993-25-005299 · form4.xml · nonDerivative · entry 2

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,690

F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.03 to 7.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-005299 · form4.xml · nonDerivative · entry 1

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,959,249

F3 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004800 · form4.xml · nonDerivative · entry 2

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,685

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.64 to $8.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-004811 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 588,249

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004811 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 607,710

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,061,467

F2 · kind: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 4, 2022, with respect to the three-year period ending on March 4, 2025. The issuer certified the achievement of the performance goals on March 5, 2025. The performance share units vested on March 5, 2025.

SEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,814,350

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,850,495

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004818 · form4.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 332,846

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004818 · form4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,636

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 4

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,010

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 3

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,974

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 2

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 276,227

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004810 · form4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,279,524

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004810 · form4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,335,577

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004817 · form4.xml · nonDerivative · entry 2

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,238

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004815 · form4.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 392,723

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004815 · form4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 395,788

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-004806 · form4.xml · derivative · entry 2

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,726

Underlying: Common Stock · 23,726 shares

Expires 2035-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-25-004806 · form4.xml · nonDerivative · entry 1

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,629

SEC source: 0001062993-25-004811 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 647,754

SEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,931,701

SEC source: 0001062993-25-004818 · form4.xml · derivative · entry 5

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,024

Underlying: Common Stock · 150,024 shares

Expires 2035-03-04

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-25-004818 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353,721

SEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,330

SEC source: 0001062993-25-004810 · form4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,376,180

SEC source: 0001062993-25-004817 · form4.xml · derivative · entry 3

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,029

Underlying: Common Stock · 180,029 shares

Expires 2035-03-04

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-25-004817 · form4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,261

SEC source: 0001062993-25-004815 · form4.xml · derivative · entry 4

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,027

Underlying: Common Stock · 165,027 shares

Expires 2035-03-04

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-25-004815 · form4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,388

SEC source: 0001062993-25-004807 · form4.xml · derivative · entry 2

Pellini Michael J · CIK 0001402017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,726

Underlying: Common Stock · 23,726 shares

Expires 2035-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-25-004807 · form4.xml · nonDerivative · entry 1

Pellini Michael J · CIK 0001402017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,690

SEC source: 0001062993-25-004805 · form4.xml · derivative · entry 2

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,726

Underlying: Common Stock · 23,726 shares

Expires 2035-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-25-004805 · form4.xml · nonDerivative · entry 1

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,690

SEC source: 0001062993-25-004803 · form4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,726

Underlying: Common Stock · 23,726 shares

Expires 2035-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-25-004803 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,690

SEC source: 0001062993-25-004800 · form4.xml · derivative · entry 3

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,726

Underlying: Common Stock · 23,726 shares

Expires 2035-03-04

F3 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.